Carenet Health Recognized as Major Contender in 2025 Everest Group Care Management PEAK Matrix®

Carenet Health Recognized as Major Contender in Everest Group’s 2025 PEAK Matrix® for Clinical and Care Management Operations Platforms Carenet Health has been formally recognized as a Major Contender in the 2025 PEAK Matrix® Assessment conducted by Everest Group for…

Read MoreCarenet Health Recognized as Major Contender in 2025 Everest Group Care Management PEAK Matrix®

$1M Stephenson Prize Awarded to Dr. Frank McCormick for Pancreatic Cancer Research

Dr. Frank McCormick Receives Inaugural $1 Million Stephenson Global Prize for Pancreatic Cancer Research In a landmark moment for the global cancer research community, Dr. Frank McCormick has been awarded the inaugural Stephenson Global Prize, recognizing his groundbreaking contributions to…

Read More$1M Stephenson Prize Awarded to Dr. Frank McCormick for Pancreatic Cancer Research
Sarepta

Alpha Cognition Inc. Announces $35 Million Oversubscribed Public Offering of Common Shares

Alpha Cognition Inc, a commercial‑stage biopharmaceutical enterprise committed to advancing therapies for neurodegenerative diseases, today announced the successful pricing of an oversubscribed underwritten public offering of its common shares. Under the terms of the offering, the Company is issuing 5,600,000…

Read MoreAlpha Cognition Inc. Announces $35 Million Oversubscribed Public Offering of Common Shares

Aarvik Therapeutics Secures Funding with Successful Series Seed 2 Round

Aarvik Therapeutics Closes Series Seed 2 Financing Round, Accelerating Development of Next-Generation Cancer Therapies Aarvik Therapeutics, a pioneering biotechnology company specializing in antibody-drug conjugates (ADCs) and committed to advancing precision medicine in oncology, has announced the successful completion of its…

Read MoreAarvik Therapeutics Secures Funding with Successful Series Seed 2 Round

TAE Life Sciences’ Novel Boron Drugs for BNCT Show Enhanced Tumor Suppression with Immunotherapy in Preclinical Models

TAE Life Sciences’ Next-Generation Boron Drugs Show Promising Synergy with Immunotherapy in Preclinical BNCT Studies TAE Life Sciences (TLS), a leading biotechnology company focused on next-generation cancer therapies, today announced compelling preclinical results from its ongoing collaboration with Kyoto University.…

Read MoreTAE Life Sciences’ Novel Boron Drugs for BNCT Show Enhanced Tumor Suppression with Immunotherapy in Preclinical Models